Medication info

Boryung Pregabalin Capsule 25 mg

Prescription medicationOralExpired
Ingredient · strength
Pregabalin›25mg / 1 capsule
Manufacturer / importer
Boryung Co., Ltd.
Appearance
A hard capsule with a pale yellow upper part and a white lower part containing white or pale yellow powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Expired

MFDS item code 202001637 · Approved 2020.03.10

This product's status changed to Expired on 2025.03.10. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is excreted primarily by the kidneys; therefore, the dose should be adjusted in patients with renal impairment. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’.) 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is excreted primarily by the kidneys as unchanged drug after systemic circulation. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with renal impairment should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with renal impairment.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Boryung Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary general symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve peripheral and central neuropathic pain in adults. It is also used as an adjunct in the treatment of partial seizures in patients with epilepsy, applicable in cases with or without secondary generalization. It is additionally effective in treating fibromyalgia. Overall, it is used for the improvement of neuralgia, epilepsy, and muscle pain.

How to take

Adult dose

Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, with or without food. This medicine is excreted primarily by the kidneys; therefore, the dose should be adjusted in patients with renal impairment. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of administration’.) 2. Epilepsy Adults: The initial dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of administration Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is excreted primarily by the kidneys as unchanged drug after systemic circulation. Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with renal impairment should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60 mL/min: Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30 -<60 mL/min: Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15 -<30 mL/min: Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15 mL/min: Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: 25 mg, maximum dose 100 mg, single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified in the administration schedule. b: A supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (65 years and older) Dose reduction may be necessary in older adults with renal impairment.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication is an anticonvulsant, and during treatment, suicidal thoughts or behaviors, emergence or worsening of depression, and unusual changes in mood or behavior must be carefully monitored. Patients with hypersensitivity to this medication or genetic lactose intolerance should not take it. Diabetic patients may need to adjust their blood sugar-lowering medication dosages due to weight gain. If symptoms of hypersensitivity, such as angioedema, occur, discontinue the medication immediately. Elderly patients should be cautious during initial dosing due to increased fall risk from dizziness and drowsiness. Vision changes or blurred vision may occur, but these symptoms may improve upon discontinuation of the medication. When switching to this medication as monotherapy, caution is advised due to insufficient data on the discontinuation of existing anticonvulsants. Withdrawal symptoms such as insomnia, headache, nausea, and anxiety can occur upon discontinuation, so it is advisable to taper off gradually. Patients with a history of drug abuse should be closely monitored as the risk of abuse may be higher with this medication. Dose adjustment may be necessary for patients with renal impairment, and there have been reports of improved renal function after discontinuation of the medication. Patients with heart disease should use this medication cautiously considering the risk of congestive heart failure. Caution is necessary when used in combination with opioid analgesics due to increased risk of central nervous system depression. Patients with respiratory or neurological diseases or the elderly are at heightened risk for severe respiratory depression and should have their doses adjusted. In early pregnancy, caution is advised due to the risk of fetal malformations, and effective contraception should be used in women of childbearing age. This medication may pass into breast milk, so breastfeeding should be discontinued or the medication considered for discontinuation. This medication can cause dizziness and drowsiness, so caution is needed before driving or operating dangerous machinery. Severe skin reactions may occur rarely, so if skin abnormalities appear, discontinue use and consult a healthcare professional immediately. In the event of overdose, symptoms such as altered consciousness, confusion, depression, and seizures may occur, necessitating immediate medical treatment. Keep out of reach of children, and it is safer not to change the container for storage.

Side effects

suicidal impulses, suicidal behavior, depression, abnormal mood and behavior changes, angioedema, facial swelling, perioral edema, upper airway edema, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, thoughts of suicide, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, appetite loss, hypoglycemia, confusion, disorientation, irritability, feelings of contentment, decreased libido, depersonalization, sexual sensation abnormalities, restlessness, anxiety, mood swings, emotional decline, emotional elevation, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, inability to control, apathy, ataxia, motor coordination abnormalities, balance disorders, amnesia, attention disorders, memory disorders, tremors, dysarthria, sensory abnormalities, sensory loss, sedation, drowsiness, cognitive impairment, nystagmus, speech disorders, myoclonic jerks, decreased reflexes, motor abnormalities, psychomotor agitation, positional vertigo, hypersensitivity, burning sensation, rest tremor, syncope, malaise, motor decrease syndrome, olfactory abnormalities, loss of taste, writing difficulty, diplopia, auditory hypersensitivity, first-degree atrioventricular block, tachycardia, homogenous bradycardia, homogenous tachycardia, homogenous arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, nasal bleeding, cough, nasal congestion, rhinitis, snoring, pharyngeal tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, decreased urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, breast enlargement, peripheral edema, edema, gait abnormalities, falls, feeling drunk, sensation abnormalities, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased serum creatine phosphokinase, increased aspartate aminotransferase, increased blood sugar, decreased platelet count, decreased serum potassium, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reaction, headache, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, affective disorder, drowsiness, state of confusion, agitation, restlessness, worsening of seizures, gastrointestinal disorders, tinnitus, sleep disorders, skin diseases, increased BUN, bloody stools, shock, anaphylactoid symptoms, skin and mucous membrane syndrome, erythema multiforme

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. Recommended storage temperature is at room temperature between 15 to 30 degrees Celsius to maintain the drug's efficacy for a longer period.

Appearance and packaging

Appearance

A hard capsule with a pale yellow upper part and a white lower part containing white or pale yellow powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.